Targeting adenosine receptor 2B in triple negative breast cancer

References

[1] Dietze EC,Miranda-Carboni G,Seewaldt VL.Triple-negative breast cancer in African-American women: disparities versus biology..Nat Rev Cancer2015;15:248-54 PMCID:PMC5470637

[2] Lindner R,Offor O,Halligan K,Shah M,Schulz V,Harris LN.Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy..PLoS One2013;8:e71915

[3] Foulkes WD,Reis-Filho JS.Triple-negative breast cancer..N Engl J Med2010;363:1938-48

[4] Loi S,Piette F,Viale G,Rouas G,Crown JP,de Azambuja E,Di Leo A,Piccart MJ.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98..J Clin Oncol2013;31:860-7

[5] Loi S,Salgado R,Jose V,Kellokumpu-Lehtinen PL,Kataja V,Piccart MJ,Denkert C,Joensuu H.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial..Ann Oncol2014;25:1544-50

[6] Salgado R,Campbell C,Nuciforo P,de Azambuja E,Ellis CE,Piccart-Gebhart MJ,Bradbury I,Loi S.Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO Trial..JAMA Oncol2015;1:448-54 PMCID:PMC5551492

[7] Denkert C,Noske A,Muller BM,Budczies J,Kronenwett R,von Torne C,Engels K,Schrader I,von Minckwitz G.Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer..J Clin Oncol2010;28:105-13

[8] Ono M,Shimizu C,Shibata T,Hirata T,Ando M,Katsumata N,Takiguchi Y,Fujiwara Y.Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer..Breast Cancer Res Treat2012;132:793-805

[9] Denkert C,Brase JC,Gade S,Pfitzner BM,Loi S,Schem C,Darb-Esfahani S,Sotiriou C,Klare P,Klauschen F,Krappmann K,Tesch H,Sinn P,Dietel M,Untch M.Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers..J Clin Oncol2015;33:983-91

[10] Santoni M,Saladino T,Guarino S,Giannini M,Ferrara G.Triple negative breast cancer: key role of tumor-associated macrophages in regulating the activity of anti-PD-1/PD-L1 agents..Biochim Biophys Acta2018;1869:78-84

[11] Yuan ZY,Peng RJ,Xue C.High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis..Oncol Targets Ther2014;7:1475-80 PMCID:PMC4149399

[12] Frankenberger C,Bainer R,Chada K,Gilad Y,Rosner MR.Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages..Cancer Res2015;75:4063-73 PMCID:PMC4592465

[13] Marvel D.Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected..J Clin Invest2015;125:3356-64 PMCID:PMC4588239

[14] Condamine T,Youn JI.Regulation of tumor metastasis by myeloid-derived suppressor cells..Annu Rev Med2015;66:97-110 PMCID:PMC4324727

[15] Ouzounova M,Piranlioglu R,Kolhe R,Marasco D,Chadli A,Thangaraju M,Arbab AS,Korkaya H.Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade..Nat Commun2017;8:14979 PMCID:PMC5384228

[16] Wesolowski R,Stiff A,Trikha P,Schoenfield L,Layman R,Macrae ER,Reinbolt RE,Byrd JC,Mace TA.Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer..Cancer Immunol Immunother2017;66:1437-47

[17] Lehmann BD,Chen X,Johnson KN,Moses HL,Pietenpol JA.Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection..PLoS One2016;11:e0157368

[18] Lehmann BD,Chen X,Chakravarthy AB,Pietenpol JA.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies..J Clin Invest2011;121:2750-67 PMCID:PMC3127435

[19] Linden J.Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection..Annu Rev Pharmacol Toxicol2001;41:775-87

[20] Koeppen M,Eltzschig HK.Interplay of hypoxia and A2B adenosine receptors in tissue protection..Adv Pharmacol2011;61:145-86

[21] Cronstein BN,Nichols D,Williams M.The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively..J Clin Invest1990;85:1150-7 PMCID:PMC296546

[22] Novitskiy SV,Zaynagetdinov R,Huang Y,Blackburn MR,Carbone DP,Dikov MM.Adenosine receptors in regulation of dendritic cell differentiation and function..Blood2008;112:1822-31 PMCID:PMC2518889

[23] Lukashev D,Ohta A.From "Hellstrom Paradox" to anti-adenosinergic cancer immunotherapy..Purinergic Signal2007;3:129-34 PMCID:PMC2096757

[24] Ehrentraut H,Eltzschig HK.Adora2b adenosine receptor engagement enhances regulatory T cell abundance during endotoxin-induced pulmonary inflammation..PLoS One2012;7:e32416

[25] Ohta A.A metabolic immune checkpoint: adenosine in tumor microenvironment..Front Immunol2016;7:109 PMCID:PMC4809887

[26] Iannone R,Maiolino P,Morello S.Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma..Neoplasia2013;15:1400-9 PMCID:PMC3884531

[27] Young A,Barkauskas DS,Hay C,Huang Q,Takeda K,Sachsenmeier K.Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses..Cancer Cell2016;30:391-403

[28] Leone RD,Powell JD.A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy..Comput Struct Biotechnol J2015;13:265-72 PMCID:PMC4415113

[29] Sorrentino C,Porta A,Morello S.Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression..Oncotarget2016;7:64274-88 PMCID:PMC5325441

[30] Curtis C,Chin SF,Rueda OM,Speed D,Samarajiwa S,Graf S,Haffari G,Russell R,Group M,Green A,Wishart G,Watson P,Murphy L,Purushotham A,Brenton JD,Caldas C.The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups..Nature2012;486:346-52

[31] Alluri P.Basal-like and triple-negative breast cancers: searching for positives among many negatives..Surg Oncol Clin N Am2014;23:567-77 PMCID:PMC4304394

[32] Perou CM,Eisen MB,Jeffrey SS,Pollack JR,Johnsen H,Fluge O,Williams C,Lonning PE,Brown PO.Molecular portraits of human breast tumours..Nature2000;406:747-52

[33] Loi S,Haibe-Kains B,Darcy PK,Stagg J.CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer..Proc Natl Acad Sci U S A2013;110:11091-6 PMCID:PMC3704029

[34] Buisseret L,Allard B,Bergeron M,Ameye L,Paesmans M,Di Leo A,Piccart-Gebhart M,Sotiriou C.Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial..Ann Oncol2017;

[35] Taylor NA,Iglesia MD,Midkiff BR,Reisdorf S,Carey LA,Perou CM,Serody JS.Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer..J Clin Invest2017;127:3472-83 PMCID:PMC5669567

[36] Panjehpour M,Klotz KN.Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal..Br J Pharmacol2005;145:211-8 PMCID:PMC1576131

[37] Fernandez-Gallardo M,Sandoval A,Monjaraz E.Adenosine stimulate proliferation and migration in triple negative breast cancer cells..PLoS One2016;11:e0167445

[38] Stagg J,McLaughlin N,Pommey S,Dwyer KM.Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis..Proc Natl Acad Sci U S A2010;107:1547-52 PMCID:PMC2824381

[39] Mittal D,Barkauskas D,Kalimutho M,Caramia F,Stagg J,Loi S.Adenosine 2B receptor expression on cancer cells promotes metastasis..Cancer Res2016;76:4372-82

[40] Desmet CJ,Prieur A,Visser NL,Smit MA,Laoukili J,Rodenko B,Evers B,Ajouaou A,van Vliet M,Wessels LF.Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis..Proc Natl Acad Sci U S A2013;110:5139-44 PMCID:PMC3612632

[41] Bernardi R.Hallmarks of triple negative breast cancer emerging at last?.Cell Res2014;24:904-5

[42] Pusztai L,Hofstatter EW,Horowitz NR,Killelea BK,Szekely B,Rispoli L.Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): a phase I/II trial..J Clin Oncol2017;35 Suppl 15:abstr572